Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial.

@article{Okines2010EpirubicinOA,
  title={Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial.},
  author={Alicia Okines and Sue E Ashley and D. Hamish Cunningham and Jacqueline R Oates and Andrea Turner and Janine K Webb and Claire Saffery and Yu Jo Chua and Ian Chau},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2010},
  volume={28 25},
  pages={3945-50}
}
PURPOSE Epirubicin, oxaliplatin, and capecitabine (EOC) is a standard treatment in advanced esophagogastric cancer. Panitumumab (P) is a fully human, immunoglobulin G2 monoclonal antibody targeting epidermal growth factor receptor. Randomized Trial of EOC +/- Panitumumab for Advanced and Locally Advanced Esophagogastric Cancer (REAL-3) will evaluate whether the addition of P to EOC improves survival in patients with advanced esophagogastric adenocarcinoma and undifferentiated carcinoma… CONTINUE READING
45 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 45 extracted citations

Similar Papers

Loading similar papers…